Cartilage oligomeric matrix protein neoepitope in the synovial fluid of horses with acute lameness: A new biomarker for the early stages of osteoarthritis.
Authors: Skiöldebrand E, Ekman S, Mattsson Hultén L, Svala E, Björkman K, Lindahl A, Lundqvist A, Önnerfjord P, Sihlbom C, Rüetschi U
Journal: Equine veterinary journal
Summary
# Editorial Summary Identifying osteoarthritis in its earliest stages remains one of equine practice's most challenging diagnostic problems, as traditional imaging and clinical examination often miss the initial cartilage damage that precedes structural lesions. Researchers developed a novel biomarker by identifying a specific fragment of cartilage oligomeric matrix protein (COMP) that is released when cartilage is degraded, then created a custom ELISA test to detect this neoepitope in synovial fluid samples from healthy horses and those with varying degrees of lameness and OA. The COMP neoepitope concentration was significantly elevated in fluid from acutely lame joints compared to normal joints, chronically lame joints, and joints with established structural OA—a distinctive pattern suggesting this marker specifically reflects the acute inflammatory cascade triggering cartilage breakdown. This finding has substantial clinical potential: a synovial fluid biomarker capable of detecting cartilage damage before imaging abnormalities appear could transform early diagnosis and intervention protocols, allowing practitioners to instigate treatment during the critical window when damage may still be reversible. However, practitioners should note that the study was based on polyclonal rather than monoclonal antibodies, which may affect the assay's specificity and reproducibility in future clinical applications, and further work is needed to validate the test across larger, more diverse populations before it becomes a routine diagnostic tool.
Read the full abstract on PubMed
Practical Takeaways
- •This COMP neoepitope biomarker may enable detection of early cartilage damage before structural lesions appear on imaging, potentially allowing earlier intervention in lame horses
- •A synovial fluid test based on this biomarker could help differentiate acute cartilage injury from chronic OA, informing prognosis and treatment decisions
- •Further validation in clinical populations is needed before this assay can be adopted as a routine diagnostic tool in practice
Key Findings
- •A novel COMP neoepitope (sequence SGPTHEGVC) was identified and quantified from cartilage explants stimulated with interleukin-1β
- •COMP neoepitope concentration in synovial fluid was significantly elevated in joints with acute lameness compared to normal joints (P<0.05)
- •COMP neoepitope levels in acute lameness were significantly higher than in chronically lame horses and those with chronic structural OA
- •Immunolabelling showed pericellular localization of the neoepitope in interleukin-1β-stimulated cartilage explants